| Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.Arthritis Res Ther | PMID 37194094PMC10186767 | 2023-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 37116523无 PMCID | 2023-May-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.N Engl J Med | PMID 37163621无 PMCID | 2023-May-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.N Engl J Med | PMID 37163622无 PMCID | 2023-May-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.N Engl J Med | PMID 37163623PMC10257898 | 2023-May-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 37146426无 PMCID | 2023-May-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.Transl Psychiatry | PMID 37164957PMC10171157 | 2023-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.Blood Cancer J | PMID 37156782PMC10166682 | 2023-May-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design.Trials | PMID 37143158PMC10157966 | 2023-May-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.Clin Infect Dis | PMID 36660819PMC10156123 | 2023-May-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.Rheumatology (Oxford) | PMID 36130275PMC10152297 | 2023-May-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.J Clin Oncol | PMID 36623230PMC10150922 | 2023-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.J Clin Oncol | PMID 36706347无 PMCID | 2023-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated With Adjuvant Radiation for Early-Stage Breast Cancer.Int J Radiat Oncol Biol Phys | PMID 36724858无 PMCID | 2023-May-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.Invest Radiol | PMID 36729404PMC10090311 | 2023-May-01 | 0.95 | The trial is a randomized, phase III study of a contrast agent (gadopiclenol) for MRI, not a therapeutic oncology trial. It evaluates diagnostic imaging efficacy and safety, not time-to-event clinical outcomes like survival or progression. | 待处理 |
| Phase III Randomized Non-Inferiority Study of OSS Versus PEG + Electrolyte Colonoscopy Preparation in Adolescents.J Pediatr Gastroenterol Nutr | PMID 36821851PMC10097489 | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.Clin J Am Soc Nephrol | PMID 36927680PMC10278789 | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).Int J Gynecol Cancer | PMID 36997229无 PMCID | 2023-May-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Levonorgestrel 52-mg Intrauterine Device Efficacy and Safety After More Than 8 Years of Use.Obstet Gynecol | PMID 37023451无 PMCID | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The comparison of efficacy and safety evaluation of vacuum-assisted Elite 10-G system and the traditional BARD 14-G core needle in breast diagnosis: an open-label, parallel, randomized controlled trial.Int J Surg | PMID 37042316PMC10389332 | 2023-May-01 | 0.95 | This is a Phase 3 randomized trial in oncology (breast cancer diagnosis), but it compares two diagnostic biopsy procedures (vacuum-assisted vs. core needle) and does not involve a drug intervention. The primary efficacy endpoint is diagnostic accuracy (a proportion), not a time-to-event endpoint such as OS, PFS, or DFS. Therefore, it does not meet the criteria for a drug-containing oncology trial with a time-to-event efficacy endpoint. | 待处理 |
| Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA Netw Open | PMID 37129897PMC10155068 | 2023-May-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.JAMA Netw Open | PMID 37133864PMC10157429 | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.JAMA Netw Open | PMID 37184839PMC12520708 | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.JAMA Netw Open | PMID 37195664PMC10193180 | 2023-May-01 | 0.80 | This is a cross-sectional methodological study analyzing changes in primary endpoints among phase 3 oncology RCTs. It is not a report of an original trial result with a drug intervention and a time-to-event efficacy endpoint. The study itself is observational and methodological, not an eligible trial report. | 待处理 |
| Testing a Novel Deliberate Practice Intervention to Improve Diagnostic Reasoning in Trauma Triage: A Pilot Randomized Clinical Trial.JAMA Netw Open | PMID 37195666PMC10193186 | 2023-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.JAMA Netw Open | PMID 37195667PMC10193185 | 2023-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.Diabetes Obes Metab | PMID 36633505无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.J Asthma | PMID 36066123无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.Lancet Respir Med | PMID 36528039PMC9891737 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.Am J Kidney Dis | PMID 36535535无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.J Am Acad Dermatol | PMID 36574595无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.Ophthalmology | PMID 36574848无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.Diabetes Obes Metab | PMID 36594724无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease.J Clin Pharmacol | PMID 36601737无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.Lancet Infect Dis | PMID 36638819无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.J Thorac Oncol | PMID 36646210无 PMCID | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months.Int J Infect Dis | PMID 36682682无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.Lancet Respir Med | PMID 36702146无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.Clin Rheumatol | PMID 36715850PMC9886207 | 2023-May | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).J Neurol | PMID 36735057PMC9897618 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.Headache | PMID 36797223无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study.Clin Transl Sci | PMID 36799346PMC10176010 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.Clin Transl Sci | PMID 36824016PMC10176008 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial.Complement Ther Med | PMID 36842634无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).Am J Clin Dermatol | PMID 36855020PMC9974384 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.Ann Oncol | PMID 36858151无 PMCID | 2023-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.Psychiatry Res | PMID 36878177无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.BioDrugs | PMID 36881323PMC10195725 | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.J Dermatol | PMID 36882942无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Eur J Cancer | PMID 36893711PMC10585240 | 2023-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |